Related Experiment Video
Updated: Aug 7, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Targeted toxins in brain tumor therapy
Yan Michael Li1, Walter A Hall
1Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13210, NY, USA. liy@upstate.edu
Abstract:
Targeted toxins, also known as immunotoxins or cytotoxins, are recombinant molecules that specifically bind to cell surface receptors that are overexpressed in cancer and the toxin component kills the cell. These recombinant proteins consist of a specific antibody or ligand coupled to a protein toxin. The targeted toxins bind to a surface antigen or receptor overexpressed in tumors, such as the epidermal growth factor receptor or interleukin-13 receptor. The toxin part of the molecule in all clinically used toxins is modified from bacterial or plant toxins, fused to an antibody or carrier ligand. Targeted toxins are very effective against cancer cells resistant to radiation and chemotherapy. They are far more potent than any known chemotherapy drug. Targeted toxins have shown an acceptable profile of toxicity and safety in early clinical studies and have demonstrated evidence of a tumor response. Currently, clinical trials with some targeted toxins are complete and the final results are pending. This review summarizes the characteristics of targeted toxins and the key findings of the important clinical studies with targeted toxins in malignant brain tumor patients. Obstacles to successful treatment of malignant brain tumors include poor penetration into tumor masses, the immune response to the toxin component and cancer heterogeneity. Strategies to overcome these limitations are being pursued in the current generation of targeted toxins.
Insights
Targeted toxins, novel cancer therapies, bind to tumor cells and kill them. Clinical trials show promise for treating brain tumors, with ongoing research to overcome treatment challenges.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Targeted toxins, also known as immunotoxins, are engineered proteins combining antibodies/ligands with toxins.
- They selectively target cell surface receptors overexpressed on cancer cells, like EGFR or IL-13R.
- These toxins offer a potent alternative to conventional chemotherapy, especially for resistant cancers.
Purpose of the Study:
- To review the characteristics of targeted toxins.
- To summarize key findings from clinical studies of targeted toxins in malignant brain tumor patients.
- To discuss obstacles and strategies for improving targeted toxin therapy.
Main Methods:
- Review of existing literature on targeted toxins and their clinical applications.
- Analysis of clinical trial data for targeted toxins in brain tumor treatment.
- Identification of challenges such as tumor penetration, immunogenicity, and tumor heterogeneity.
Main Results:
- Targeted toxins demonstrate high potency against cancer cells, exceeding chemotherapy drugs.
- Early clinical studies show an acceptable safety profile and evidence of tumor response.
- Clinical trials are ongoing, with final results pending for several targeted toxins.
Conclusions:
- Targeted toxins represent a promising therapeutic strategy for malignant brain tumors.
- Overcoming challenges like poor tumor penetration and immune response is crucial for next-generation targeted toxins.
- Further research and clinical trials are essential to optimize their efficacy and application.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy